Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update

Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any sp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nicia I. Profili, Roberto Castelli, Antonio Gidaro, Roberto Manetti, Margherita Maioli, Alessandro P. Delitala
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Pharmaceuticals
Subjects:	SGLT2i Na<sup>+</sup>-glucose cotransporter-2 inhibitors chronic heart failure acute heart failure diabetes cardiovascular disease
Online Access:	https://www.mdpi.com/1424-8247/17/11/1419
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
by: Takuma Koinuma, et al.
Published: (2024-12-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01)

Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction
by: Bin Xiong, et al.
Published: (2024-12-01)

Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
by: Ivana Jurin, et al.
Published: (2024-11-01)

The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients
by: Yibin Zhang, et al.
Published: (2024-12-01)

Study of cardiovascular risk in type 2 diabetic patients in the acute phase of the coronavirus infection and post-COVID period on the background of therapy with sodium-glucose cotransporter-2 inhibitors
by: N.M. Kushnarоva, et al.
Published: (2024-12-01)

Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure
by: Fei Li, et al.
Published: (2024-12-01)

Effect of sex on sodium‐glucose co‐transporter‐2 antagonists and glucagon‐like peptide‐1 agonists in heart failure
by: Mevin A. Philip, et al.
Published: (2024-12-01)

Antihypertensive effects of SGLT2 inhibitors; a letter to the editor on new concepts
by: Rahimeh Eskandarian, et al.
Published: (2024-06-01)

Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Ying Liu, et al.
Published: (2025-01-01)

Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
by: Amarit Tansawet, et al.
Published: (2024-11-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?
by: Aurelio Seidita, et al.
Published: (2024-11-01)

Veratridine Induces Vasorelaxation in Mouse Cecocolic Mesenteric Arteries
by: Joohee Park, et al.
Published: (2024-12-01)

LIG-Based High-Sensitivity Multiplexed Sensing System for Simultaneous Monitoring of Metabolites and Electrolytes
by: Sang Hyun Park, et al.
Published: (2024-10-01)

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms
by: Ya-ru Chen, et al.
Published: (2024-12-01)

Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta‐analysis
by: Patrick Savage, et al.
Published: (2024-12-01)

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes
by: Xie H, et al.
Published: (2024-11-01)

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world
by: Minjung Bak, et al.
Published: (2024-12-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
by: Elina Khattab, et al.
Published: (2025-01-01)

Impairment of Glucose Uptake Induced by Elevated Intracellular Ca<sup>2+</sup> in Hippocampal Neurons of Malignant Hyperthermia-Susceptible Mice
by: Arkady Uryash, et al.
Published: (2024-11-01)

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01)

Association of Seedling Vigour and Salinity Tolerance in Field Pea
by: Babu R. Pandey, et al.
Published: (2024-11-01)

Effects of sodium-glucose cotransporter-2 inhibitor on atrial high-rate episodes in patients with cardiovascular implantable electronic device: a randomized controlled trial
by: Teerapat Nantsupawat, et al.
Published: (2024-11-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition and Fluid Status in Cardiovascular Rehabilitation Patients with Coronary Artery Disease and Heart Failure
by: José C. De La Flor, et al.
Published: (2024-12-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Personalized approach in the management of women with heart failure with preserved ejection fraction and carbohydrate metabolism disorders
by: L.R. Petrovska, et al.
Published: (2024-12-01)

Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
by: Akshay Bafna, et al.
Published: (2024-04-01)

N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity
by: Stefano Comai, et al.
Published: (2024-11-01)

The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma
by: Yao Liu, et al.
Published: (2025-01-01)

Detection of Silver and Mercury Ions Using Naphthalimide-Based Fluorescent Probe
by: Chunwei Yu, et al.
Published: (2024-11-01)

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01)

The Venom of <i>Vipera ammodytes ammodytes</i>: Proteomics, Neurotoxic Effect and Neutralization by Antivenom
by: Saša R. Ivanović, et al.
Published: (2024-11-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)